Ichnos Glenmark Innovation receives upfront payment of $700 million from AbbVie

The payment is in accordance with the agreed contractual terms

Gilead Sciences breaks ground on new manufacturing and technical development site in US

New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value

Aptar Pharma partners with Dianosic to advance ARIS platform for treatment of chronic allergic rhinitis and rhinosinusitis

Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods

Zydus Lifesciences appoints Nitin Parekh as President (Special Projects)

He has been associated with the Zydus Group since 2009

Indegene opens new center in Pune

Zydus and Synthon ink licensing and supply agreement for Ozanimod Capsules for US market

Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product

Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease

RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options

Quotient Sciences and CPI join forces to accelerate RNA drug development

The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products

Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain

The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes